Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Not available
- Industry
- Not available
- ISIN
- NL00150012K9
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.11
- MarketCapitalization
- Not available
About
About NewAmsterdam Pharma Company N.V. Warrant
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Visit company website
No comments yet
Start a focused discussion about NAMSW.